

SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer

Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies

CME-Certified Live Symposium

This activity is supported by an educational grant from Stemline Therapeutics, GmbH, a Menarini Group Company.

Friday, 9 September 2022
18:00-19:30 CEST

7.3.G – Grenoble Auditorium, Hall 7, Level 7.3
Paris Expo Porte de Versailles, Paris, France



CHAIR & PRESENTER

Javier Cortes, MD, PhD
International Breast Cancer Center (IBCC)
Barcelona, Spain



PRESENTER

Aditya Bardia, MD, MPH
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts



PRESENTER

Francois-Clement Bidard, MD, PhD
Institut Curie & UVSQ/Paris Saclay University
Paris, France

Agenda

- 18:00 CEST: Symposium
 - Welcome and Introduction (*Javier Cortes, MD, PhD*)
 - Modern Approaches in the Treatment of ER+/HER2- Breast Cancer: Understanding the Biology and Foundational Concepts (*Francois-Clement Bidard, MD, PhD*)
 - ER+/HER2- Breast Cancer Pretreated With Endocrine Therapy as an Inflection Point: Unmet Needs and Novel Rational Treatment Strategies (*Javier Cortes, MD, PhD*)
 - Emerging Options in the Treatment of ER+/HER2- Breast Cancer: The Expanding Evidence Base on Oral SERDs and Other ER-Targeting Agents (*Aditya Bardia, MD, MPH*)
 - Accelerating Progress in the Treatment of Previously Treated ER+/HER2- Breast Cancer With Novel Therapies: Translating Research Advances Into Improvements in Practice (*All faculty panel discussion*)
 - Audience Q&A
- 19:30 CEST: Adjourn

Key Reasons to Attend:

- Achieve a better understanding of why resistance to endocrine therapy is an inflection point for patients with pre-treated advanced ER+/HER2- breast cancer, and what mechanisms contribute to the development of resistance
- Get current on the intense research efforts focused on addressing unmet needs in endocrine-resistant advanced ER+/HER2- breast cancer, including potentially practice-changing data on novel ER-targeting agents such as oral SERDs
- Receive practical guidance on how to integrate the new oral SERDs and other ER-targeting therapies into practice for appropriate patients